Tag: ACAD

  • Investors May Want to Use ACADIA Weakness as Opportunity

    Investors May Want to Use ACADIA Weakness as Opportunity

    Don’t write off ACADIA Pharmaceuticals (ACAD) just yet. In early March, the stock gapped from about $45.50 to $20.63.  All after the US FDA rejected its drug to treat hallucinations and delusions associated with dementia-related psychosis (DRP), as noted by the company. “Despite prior agreements with the Division of Psychiatry regarding the pivotal Phase 3 HARMONY study…